Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02343666CT.gov HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection | — | Withdrawn | — | — | — |
NCT02797470CT.gov Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | — | Active Not Recruiting | — | — | — |
NCT02337985CT.gov Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT00000658CT.gov A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00002070CT.gov Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis | — | Completed | — | — | — |
NCT00000689CT.gov Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma | — | Completed | — | — | — |
NCT00000989CT.gov The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · HIV Infectious Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivestim (this asset) | Fred Hutchinson Cancer Center | P3 | BB · 69 |
| Raltegravir | Helsinki University Central Hospital | P4 | A |
| Efavirenz | The Cleveland Clinic | P4 | BBB |
| Retrovir | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | P4 | BBB |
| Nevirapine Anhydrous | Germans Trias i Pujol Hospital | P4 | BBB |
| Abacavir | Germans Trias i Pujol Hospital | P4 | BBB |
| Dolutegravir | Instituto Mexicano del Seguro Social | P4 | BBB |
| NORVIR | Giovanni Di Perri | P4 | BBB |
| Pravastatin | Ospedale di Circolo - Fondazione Macchi | P4 | BBB |
+38 more in the HIV Infectious Disease cohort
Other indications for Nivestim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P4 | BBB · 78 |
| Neutropenia | — | P4 | BBB · 76 |
| Mycosis Fungoides | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivestim in HIV Infectious Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/n-met-g-csf-hiv-infectious-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →